Showing 221-230 of 490 results for "".
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- FDA Says No to Evolus' Botox Rivalhttps://modernaesthetics.com/news/fda-says-no-to-evolus-botox-rival/2472089/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Sciton Launches diVa® Center of Excellence Programhttps://modernaesthetics.com/news/sciton-launches-diva-center-of-excellence-program/2472230/Sciton, Inc.’s new diVa® Center of Excellence Program will spotlight urogynecologists, urologists, OB/GYN's and gynecologists who are dedicated to creating an optimal Treatment Experience for women. The Centers will review data and outcome
- ASAPS: Americans Spent Big on Cosmetic Surgery in 2016https://modernaesthetics.com/news/asaps-americans-spent-big-on-cosmetic-surgery-in-2016/2472257/15 + B That’s the amount of money that Americans doled out for cosmetic surgery in 2016, according to newly released statistics from the American Society for Aesthetic Plastic Surgery (ASAPS). That’s 1.5 B more then they spe
- In a Week of Surprising Acquisitions, Will Syneron Be Next?https://modernaesthetics.com/news/in-a-week-of-surprising-acquisitions-will-syneron-be-next/2472276/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Merz On The Move: Reflections On Fiscal Year 2015/16https://modernaesthetics.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2472311/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- Study: Lumenato Boosts Skin Barrier Function, Collagen and Ceramideshttps://modernaesthetics.com/news/study-lumenato-boosts-skin-barrier-function-collagen-and-ceramides/2473526/Lycored's Lumenato may improve the skin barrier function and boost collagen and ceramides after 12 weeks of daily supple
- Laseroptek's PicoLO Scores FDA 510(k) Marketing Clearancehttps://modernaesthetics.com/news/laseropteks-picolo-scores-fda-510k-marketing-clearance/2471951/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the compa
- Xact Scores Best of Hot Topics at ASAPS 2018https://modernaesthetics.com/news/xact-scores-best-of-hot-topics-at-asaps-2018/2472078/Cypris Medical, Inc.’s Xact technology took home the “Best of Hot Topics” award at the American Society for Aesthetic Plastic Surgery (AS
- TikTok Star’s Harrowing Experience with Expired Acne, Dark Spot Treatmenthttps://modernaesthetics.com/news/tiktok-stars-harrowing-experience-with-expired-acne-dark-spot-treatment-1/2473595/A TikTok star’s recent trip to the emergency room is an example of why providers should remind their patients the important of not using expired skincare products. Stephanie Margarucci, who is known on TikTok as @